Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Debu, Tripathy"'
Autor:
Hak-Sung Kim, James M. Reuben, Evan N. Cohen, Debu Tripathy, Chandra Bartholomeusz, Naoto T. Ueno, Yoo-Kyoung Sohn, Gaurav B. Chauhan, Morgan M. Green, Geoffrey Bartholomeusz, Savitri Krishnamurthy, Lakesla R. Iles, Moises J. Tacam, Venkata Lokesh Battula, Maria Gagliardi, Jihyun Park, Xiaoping Wang, Natalie W. Fowlkes
Publikováno v:
Breast Cancer Research and Treatment
Background Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype that lacks targeted therapies. Patients with TNBC have a very poor prognosis because the disease often metastasizes. New treatment approaches addressing drivers of
Autor:
Debu Tripathy, Zaid Soomro, Ryan Sun, Nuhad K. Ibrahim, Elshad Hasanov, Vicente Valero, Aya Albittar, Omar Alhalabi
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-5 (2021)
NPJ Breast Cancer
NPJ Breast Cancer
The development of brain metastases (BMs) in breast cancer (BC) patients remains a challenging complication. Current clinical practice guidelines recommend local treatment of BMs without changing systemic therapy (CST) in patients with stable extracr
Autor:
Debu Tripathy, Gregory N. Fuller, Chao Gao, Kenneth R. Hess, Sami I. Bashour, Donald F. Schomer, Nuhad K. Ibrahim
Publikováno v:
British Journal of Cancer
BackgroundCNS miliary metastasis (MiM) is poorly recognised in breast and other malignancies. Given its rarity, little epidemiologic, radiographic and clinical data are known. Although usually identified on neuroimaging, criteria for radiographic dia
Autor:
Funda Meric-Bernstam, Debu Tripathy, Bora Lim, Senthil Damodaran, Hui Chen, Qingqing Ding, Aysegul A. Sahin, Weiwei Chen, Rajyalakshmi Luthra, Sarina Anne Piha-Paul
Publikováno v:
Human Pathology. 92:32-38
Summary HER2 mutations have been reported in approximately 2% of breast cancers. Regardless of HER2 overexpression or amplification status, breast cancer with HER2 mutations may respond to HER2-targeted therapy. As HER2 mutation is rare, the clinical
Autor:
Rie K. Tahara, JM Reuben, Babita Saigal, Beth Chasen, Diane Liu, Gabriel N. Hortobagyi, T Fujii, Debu Tripathy, Senthil Damodaran, Bora Lim, NT Ueno, Hui Gao, Nuhad K. Ibrahim, Anthony Lucci, Yu Shen
Publikováno v:
Cancer Research. 79:P1-18
Background: Radium-223 dichloride (Ra-223) is a targeted alpha particle-based radiotherapeutic that has a localized cytotoxic effect on bone metastases. We sought to determine whether the circulating tumor cell (CTC) count and the presence of CTCs in
Autor:
Debu Tripathy, Yun Gong, Juhee Song, Wendy A. Woodward, Naoto T. Ueno, Emilly S. Villodre, Richard A. Larson, Savitri Krishnamurthy, Xiaoding Hu, Bisrat G. Debeb, Xiaoping Wang, Omar M. Rahal
Publikováno v:
Communications Biology
Communications Biology, Vol 4, Iss 1, Pp 1-14 (2021)
Communications Biology, Vol 4, Iss 1, Pp 1-14 (2021)
Inflammatory breast cancer (IBC) is a clinically distinct and highly aggressive form of breast cancer with rapid onset and a strong propensity to metastasize. The molecular mechanisms underlying the aggressiveness and metastatic propensity of IBC are
Autor:
Debu Tripathy, Naoto T. Ueno, Kumiko Kida, Darren W. Davis, Diane D. Liu, James M. Reuben, Carlos H. Barcenas, Takeo Fujii, Minjeong Park, Vicente Valero, Mariana Chavez-MacGregor, Fanny Le Du, Weiguo Wu
Publikováno v:
PLoS ONE, Vol 15, Iss 3, p e0229903 (2020)
PLoS ONE
PLoS ONE
BackgroundTumor cells with a mesenchymal phenotype and/or cancer stem-like cells (CSCs) are known to contribute to metastasis and drug resistance. Circulating tumor cells (CTCs) undergoing epithelial-mesenchymal transition (EMT) and CTCs reflecting a
Autor:
Sandra M. Swain, Vincent Antao, Haocheng Li, Debu Tripathy, Joyce O'Shaughnessy, Laura Chu, Ginny Mason, Peter A. Kaufman, Denise A. Yardley, Sara A. Hurvitz, Mohammad Jahanzeb, Adam Brufsky, Hope S. Rugo, Melody A. Cobleigh
Publikováno v:
The oncologist, vol 25, iss 2
The Oncologist
The Oncologist
Background Limited data exist describing real‐world treatment of de novo and recurrent HER2‐positive metastatic breast cancer (MBC). Materials and Methods The Systemic Therapies for HER2‐Positive Metastatic Breast Cancer Study (SystHERs) was a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f85b6f5b4b0427599690acf0ecde9c9
https://escholarship.org/uc/item/3141135z
https://escholarship.org/uc/item/3141135z
Autor:
Ricardo H. Alvarez, Vicente Valero, Banu Arun, Gabriel N. Hortobagyi, Nuhad K. Ibrahim, Debu Tripathy, Diane Liu, Naoto T. Ueno, Marc Uemura, Wendy Woodward, Bora Lim, Kanwal Pratap Singh Raghav, John Thomas French, Kenneth R. Hess, Bisrat G. Debeb, Stacy L. Moulder
Publikováno v:
Cancer. 124:2299-2305
Background Inflammatory breast cancer (IBC) is associated with a poor prognosis and high risk of central nervous system (CNS) metastases. Methods We retrospectively reviewed stage III-IBC patients compared with noninflammatory invasive ductal carcino
Autor:
Jeremy Mason, Naoto T. Ueno, Peter Kuhn, Debu Tripathy, Wendy A. Woodward, Takeo Fujii, Angela Chen, Paul K. Newton
Background Inflammatory breast cancer (IBC) is a rare yet aggressive variant of breast cancer with a high recurrence rate. We hypothesized that patterns of metastasis differ between IBC and non-IBC. We focused on the patterns of bone metastasis throu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce1ac359ffb8e30ee79fcecb187dbc63
https://europepmc.org/articles/PMC6795167/
https://europepmc.org/articles/PMC6795167/